Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Exploring the potential of T-cell therapy for acute lymphoblastic leukemia

Dieter Hoelzer • 12 Jun 2015
EHA 2015
Acute Lymphoblastic Leukemia Leukemia CAR-T

At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses T-cell engagement strategies for the treatment of patients with acute lymphoblastic leukemia (ALL), including bispecific antibody constructs (BiTEs); chimeric antigen-receptor (CAR) T-cells; the role of minimal residual disease (MRD) in these approaches; and the impact on patient selection for transplant.

More from Dieter Hoelzer

ALL over the years
ALL over the years
Dieter Hoelzer et al. • 29 Sep 2022
The evolving landscape of ALL therapy and the impact of MRD
15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al. • 17 May 2019
MRD negativity in ALL
1:57
MRD negativity in ALL
Dieter Hoelzer • 26 Mar 2019
CAR T-cells and BiTEs for hematological malignancies
1:59
CAR T-cells and BiTEs for hematological malignancies
Dieter Hoelzer • 26 Mar 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals